Laboratory coagulation assays and ROTEM thromboelastography in monitoring the reversal of dabigatran with FEIBA and haemofiltration

被引：0
|
作者：
Leong, J. [1 ]
Thomson, E. [1 ]
Ali, A. [1 ]
Jarrold, U. [1 ]
Kanagasabapathy, P. [1 ]
机构：
[1] Royal Infirm Edinburgh NHS Trust, Edinburgh, Midlothian, Scotland
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2013年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1119 / 1119
页数：1
相关论文
共 11 条
  • [1] Impact of dabigatran on a large panel of routine or specific coagulation assays Laboratory recommendations for monitoring of dabigatran etexilate
    Douxfils, Jonathan
    Mullier, Francois
    Robert, Severine
    Chatelain, Christian
    Chatelain, Bernard
    Dogne, Jean-Michel
    THROMBOSIS AND HAEMOSTASIS, 2012, 107 (05) : 985 - 997
  • [2] Whole blood coagulation assays ROTEM and T-TAS to monitor dabigatran treatment
    Taune, Viktor
    Wallen, Hakan
    Agren, Anna
    Gryfelt, Gunilla
    Sjovik, Carolina
    Wintler, Anna M.
    Malmstrom, Rickard E.
    Wikman, Agneta
    Skeppholm, Mika
    THROMBOSIS RESEARCH, 2017, 153 : 76 - 82
  • [3] Rifampicin and dabigatran etexilate: a place for laboratory coagulation monitoring
    Chin, Paul K. L.
    Barclay, Murray L.
    Begg, Evan J.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 75 (02) : 569 - 570
  • [4] Rifampicin and dabigatran etexilate: a place for laboratory coagulation monitoring Response
    Haertter, Sebastian
    Koenen-Bergmann, Michael
    Sharma, Ashish
    Nehmiz, Gerhard
    Lemke, Ute
    Timmer, Wolfgang
    Reilly, Paul A.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 75 (02) : 571 - 571
  • [5] Reversal of Dabigatran-induced Bleeding by Coagulation Factor Concentrates in a Rat-tail Bleeding Model and Lack of Effect on Assays of Coagulation
    van Ryn, Joanne
    Schurer, Johanna
    Kink-Eiband, Monika
    Clemens, Andreas
    ANESTHESIOLOGY, 2014, 120 (06) : 1429 - 1440
  • [6] Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity
    van Ryn, Joanne
    Stangier, Joachim
    Haertter, Sebastian
    Liesenfeld, Karl-Heinz
    Wienen, Wolfgang
    Feuring, Martin
    Clemens, Andreas
    THROMBOSIS AND HAEMOSTASIS, 2010, 103 (06) : 1116 - 1127
  • [7] Determination of dabigatran, rivaroxaban and apixaban using UPLC-MS/MS and comparison with coagulation assays for therapy monitoring
    Van de Kerkhof, D.
    Schmitz, E.
    Boonen, K.
    Van den Heuvel, D.
    Brunsveld, L.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 826 - 826
  • [8] Comparison of hemoclot to standard coagulation assays for monitoring the direct thrombin inhibitor (dabigatran) in pediatric patients: an in vitro study
    Mitchell, L. G.
    Dietrich, K.
    Stang, L.
    Etches, W.
    Qayyum, S.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 777 - 777
  • [9] Assessment of the impact of rivaroxaban on coagulation assays: Laboratory recommendations for the monitoring of rivaroxaban and review of the literature
    Douxfils, Jonathan
    Mullier, Francois
    Loosen, Claire
    Chatelain, Christian
    Chatelain, Bernard
    Dogne, Jean-Michel
    THROMBOSIS RESEARCH, 2012, 130 (06) : 956 - 966
  • [10] LMW HEPARIN (ANTI-XA) ASSAYS FOR CLINICAL MONITORING AND PHARMACOKINETIC STUDIES ON THE AUTOMATED COAGULATION LABORATORY (ACL)
    OZAWA, T
    MAMMEN, EF
    THROMBOSIS RESEARCH, 1992, 66 (04) : 287 - 298
12